List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 21 studies with search of: glioblastoma AND erlotinib
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Avastin;   Drug: Tarceva;   Drug: Temodar
2 Recruiting Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
3 Active, not recruiting Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carmustine;   Drug: erlotinib hydrochloride;   Drug: temozolomide
4 Completed Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
5 Recruiting Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Drug: sorafenib tosylate;   Drug: temsirolimus;   Drug: tipifarnib
6 Recruiting Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: erlotinib hydrochloride
7 Completed A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Condition: Glioblastoma
Intervention: Drug: Erlotinib HCl (OSI-774)
8 Active, not recruiting Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Active, not recruiting Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Drug: temozolomide;   Procedure: adjuvant therapy;   Radiation: radiation therapy
10 Active, not recruiting Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Drug: temozolomide;   Radiation: radiation therapy
11 Recruiting Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Drug: temozolomide;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
12 Active, not recruiting Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Conditions: Glioblastoma Multiforme;   Gliosarcoma
Interventions: Drug: Tarceva;   Drug: Temodar;   Procedure: Radiation Therapy
13 Terminated Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: erlotinib hydrochloride
14 Active, not recruiting Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Erlotinib, Sirolimus
15 Recruiting Ph I Dasatinib + Erlotinib in Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Erlotinib and Dasatinib
16 Active, not recruiting Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
17 Recruiting Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Radiation: radiation therapy
18 Recruiting Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Drug: sirolimus;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: high performance liquid chromatography;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Procedure: biopsy
19 Active, not recruiting Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: erlotinib hydrochloride;   Drug: temsirolimus
20 Completed Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Condition: Cancer
Intervention: Drug: erlotinib hydrochloride

Previous Page Studies Shown (1-20) Next Page (21-21)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services